Interpace Biosciences, Inc.
IDXG
$1.98
-$0.01-0.50%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 38.73M | 41.91M | 45.45M | 48.26M | 46.93M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 38.73M | 41.91M | 45.45M | 48.26M | 46.93M |
| Cost of Revenue | 14.60M | 15.92M | 17.00M | 17.28M | 17.00M |
| Gross Profit | 24.13M | 25.99M | 28.45M | 30.98M | 29.93M |
| SG&A Expenses | 18.70M | 20.73M | 21.99M | 21.45M | 21.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.94M | 37.35M | 39.73M | 39.44M | 38.82M |
| Operating Income | 4.78M | 4.57M | 5.72M | 8.82M | 8.11M |
| Income Before Tax | 3.77M | 4.10M | 4.86M | 7.91M | 6.95M |
| Income Tax Expenses | -21.21M | -1.00K | 14.00K | 18.00K | 4.00K |
| Earnings from Continuing Operations | 24.98 | 4.10 | 4.84 | 7.89 | 6.95 |
| Earnings from Discontinued Operations | -409.00K | -298.00K | -280.00K | -247.00K | -244.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.58M | 3.80M | 4.56M | 7.64M | 6.70M |
| EBIT | 4.78M | 4.57M | 5.72M | 8.82M | 8.11M |
| EBITDA | 5.21M | 4.97M | 6.10M | 9.17M | 8.41M |
| EPS Basic | 5.55 | 0.76 | 0.93 | 1.63 | 1.42 |
| Normalized Basic EPS | 0.63 | 0.58 | 0.69 | 1.12 | 0.99 |
| EPS Diluted | 0.76 | 0.27 | 0.61 | 1.31 | 1.42 |
| Normalized Diluted EPS | 0.04 | 0.01 | 0.24 | 0.67 | 0.75 |
| Average Basic Shares Outstanding | 17.70M | 17.68M | 17.64M | 17.60M | 17.55M |
| Average Diluted Shares Outstanding | 87.53M | 109.55M | 86.27M | 86.25M | 62.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |